Earnings Scheduled For March 3, 2022
Companies Reporting Before The Bell
• Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million.
58 Biggest Movers From Yesterday
Gainers
Adagio Therapeutics, Inc. (NASDAQ: ADGI) shares jumped 123.3% to settle at $14.18 on Thursday after traders circulated rumors of a reiterated Buy rating and $46 price target from Jefferies.
18 Stocks Moving in Thursday’s Pre-Market Session
Gainers
Calliditas Therapeutics AB (NASDAQ: CALT) rose 36.5% to $25.45 in pre-market trading after the company announced it was granted by the FDA accelerated approval of TARPEYO to reduce proteinuria in lgA nephropathy.
20 Stocks Moving in Monday’s Pre-Market Session
Gainers
Astra Space, Inc. (NASDAQ: ASTR) rose 39.6% to $13.30 in pre-market trading after declining around 3% on Friday. Astra Space recently reported a Q3 loss of $0.06 per share.
HUTCHMED, AstraZeneca Initiate SAMETA Global Phase III Trial of Savolitinib in Combination with PD-L1 Inhibitor IMFINZI® in Patients with MET-Driven Advanced Papillary Renal Cell Carcinoma
HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq: HCM) and AstraZeneca PLC ("AstraZeneca") (Nasdaq: AZN) have initiated SAMETA, a global Phase III study of savolitinib (ORPATHYS® in China), an oral, potent, and highly selective small molecule inhibitor of
Goldman Sachs Downgrades HUTCHMED (China) to Neutral, Announces $46 Price Target
Goldman Sachs analyst Paul Choi downgrades HUTCHMED (China) (NASDAQ:HCM) from Buy to Neutral and announces $46 price target.
HUTCHMED’s Lymphoma Candidate Secures Breakthrough Tag In China
The Center for Drug Evaluation of China’s National Medical Products Administration has granted Breakthrough Therapy Designation to HUTCHMED (China) Limited’s (NASDAQ:HCM) amdizalisib…
The Daily Biotech Pulse: MacroGenics’ Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA’s FDA Nod
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 7)